Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors by Chai, RC et al.
Histone deacetylase activity mediates acquired resistance
towards structurally diverse HSP90 inhibitors
Ryan C. Chai1,2, Jessica L. Vieusseux1, Benjamin J. Lang1,3, Chau H. Nguyen1,4, Michelle M.
Kouspou1, Kara L. Britt5,6 and John T. Price1,4,7,8
1 Department of Biochemistry and Molecular Biology, Monash University, Clayton, Vic., Australia
2 Bone Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
3 Department of Radiation Oncology, Centre for Life Sciences, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
MA, USA
4 College of Health and Biomedicine, Victoria University, Melbourne, Vic., Australia
5 Peter MacCallum Cancer Centre, Melbourne, Vic., Australia
6 The Sir Peter MacCallum Department of Oncology, University of Melbourne, Vic., Australia
7 Australian Institute for Musculoskeletal Science (AIMSS), Victoria University and University of Melbourne, Vic., Australia
8 Department of Medicine, Melbourne Medical School-Western Precinct, The University of Melbourne, St Albans, Vic., Australia
Keywords
17-AAG; acquired resistance; cancer;
histone deacetylases; HSP90
Correspondence
J. T. Price, College of Health and
Biomedicine, St Albans Campus, Victoria
University, PO Box 14428, Melbourne, Vic.
8001, Australia
Tel: +613 9919 2046
E-mail: john.price@vu.edu.au
(Received 6 November 2016, revised 30
January 2017, accepted 1 March 2017,
available online 11 April 2017)
doi:10.1002/1878-0261.12054
Heat shock protein 90 (HSP90) regulates multiple signalling pathways critical
for tumour growth. As such, HSP90 inhibitors have been shown to act as effec-
tive anticancer agents in preclinical studies but, for a number of reasons, the
same effect has not been observed in the clinical trials to date. One potential
reason for this may be the presence of de novo or acquired resistance within
the tumours. To investigate mechanisms of resistance, we generated resistant
cell lines through gradual dose escalation of the HSP90 inhibitor 17-allyla-
mino-17-demethoxygeldanamycin (17-AAG). The resultant resistant cell lines
maintained their respective levels of resistance (7–2409) in the absence of 17-
AAG and were also cross-resistant with other benzoquinone ansamycin HSP90
inhibitors. Expression of members of the histone deacetylase family (HDAC 1,
5, 6) was altered in the resistant cells. To determine whether HDAC activity
contributed to resistance, pan-HDAC inhibitors (TSA and LBH589) and the
class II HDAC-specific inhibitor SNDX275 were found to resensitize resistant
cells towards 17-AAG and 17-dimethylaminoethylamino-17-demethoxygeldana-
mycin. Most significantly, resistant cells were also identified as cross-resistant
towards structurally distinct HSP90 inhibitors such as radicicol and the second-
generation HSP90 inhibitors CCT018159, VER50589 and AUY922. HDAC
inhibition also resensitized resistant cells towards these classes of HSP90 inhibi-
tors. In conclusion, we report that prolonged 17-AAG treatment results in
acquired resistance of cancer cells towards not just 17-AAG but also to a spec-
trum of structurally distinct HSP90 inhibitors. This acquired resistance can be
inhibited using clinically relevant HDAC inhibitors. This work supports the
potential benefit of using HSP90 and HDAC inhibitors in combination within
the clinical setting.
Abbreviations
17-AAG, 17-allylamino-17-demethoxygeldanamycin; 17-DMAG, 17-dimethylaminoethylamino-17-demethoxygeldanamycin; 5-FU, 5-fluorouracil;
Ac-H3, acetylated histone 3; BA, benzoquinone ansamycin; ER, endoplasmic reticulum; FBS, fetal bovine serum; GA, geldanamycin; HAT,
histone acetyltransferase; HDAC, histone deacetylase; HSF1, heat shock factor 1; HSP90, heat shock protein 90; MDR, multiple drug
resistance; NQO1, NAD(P)H: quinone oxidoreductase; P-gp, p-glycoprotein; RB, retinoblastoma protein; SRB, sulforhodamine B; STR, short
tandem repeat; TCA, trichloroacetic acid; TSA, trichostatin A.
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1. Introduction
Heat shock protein 90 (HSP90) is a molecular chaper-
one required for the biogenesis, stabilization and fold-
ing of many cellular proteins under both physiological
and pathophysiological conditions. With respect to
cancer, many client proteins of HSP90 are overex-
pressed and/or mutated oncoproteins, essential for
cancer cell survival, growth and invasive potential (da
Rocha Dias et al., 2005; Sato et al., 2000; Xu et al.,
2001). Consistent with this, high HSP90 expression is
observed in the majority of cancers enabling them to
maintain functionally active oncoproteins (Whitesell
and Lindquist, 2005). Therefore, cancer cells are
dependent on HSP90 for growth and survival, and
thus, HSP90 has emerged as a major therapeutic target
for many cancer types.
Central to its function, HSP90 contains an ATP-
binding/ATPase activity domain within its N-terminal
region (Jhaveri et al., 2012). Geldanamycin (GA), a
member of the benzoquinone ansamycin (BA) family
of antibiotics, binds to this site and inhibits HSP90
functionality resulting in the depletion of its oncogenic
client proteins via the ubiquitin-proteasome pathway
(Trepel et al., 2010). Although GA was identified as
an effective HSP90 inhibitor, its clinical development
was limited due to its hepatotoxicity in preclinical
models (Page et al., 1997). Thus, the generation of GA
derivatives more appropriate for clinical development
led to the identification of a number of compounds
including 17-allylamino-17-demethoxygeldanamycin
(17-AAG), which became the first HSP90 inhibitor to
undergo clinical cancer trials, providing ‘proof-of-con-
cept’ studies for the use of HSP90 inhibitors as anti-
cancer agents (Jhaveri et al., 2012). Currently, a
number of next-generation structurally distinct HSP90
inhibitors, many generated by rational drug design
methodologies, are in clinical evaluation, both as single
agents and in combination regimes (Butler et al., 2015;
Tatokoro et al., 2015; Wang et al., 2016; Yong et al.,
2016).
To date, limited objective clinical outcomes have
been reported in early-phase clinical trials of HSP90
inhibitors in a variety of cancers (Butler et al., 2015;
Heath et al., 2008; Ronnen et al., 2006; Solit et al.,
2008). Preclinical and clinical data have highlighted a
number of potential reasons for this including dose-
limiting toxicities such as ocular toxicity, the inability
to stratify patients who would most likely benefit from
HSP90 inhibitor treatment as well as the potential of
the tumours to be resistant or acquire resistance
towards HSP90 inhibitors limiting their overall efficacy
(Butler et al., 2015). Pre-existing (de novo) and
acquired resistance towards anticancer drugs is a com-
mon feature in many cancers, thereby reducing their
overall sensitivity towards first-line chemotherapeutic
treatments and targeted therapies. Although it was ini-
tially postulated that de novo and/or acquired resis-
tance towards HSP90 inhibitors would be rare, due to
HSP900s central involvement in multiple concurrent
pathways, it has emerged that mechanisms of resis-
tance can exist. These studies have been primarily
based upon the benzoquinone ansamycin (BA) family
of antibiotics such as GA and 17-AAG and has
demonstrated that some key determinants of cellular
resistance include high expression levels of client onco-
proteins such as HER2 (Smith et al., 2001), the heat
shock transcription factor 1 (HSF1) (Chen et al.,
2013) and other heat shock proteins as well as HSP90
co-chaperones (Guo et al., 2005; Holmes et al., 2008;
McCollum et al., 2006). Cell cycle and apoptotic regu-
lators, including the retinoblastoma protein (RB), p53,
BAGs, and BAX, have also been shown to contribute
to the sensitivity of cells towards HSP90 inhibitors
(Maloney et al., 2003). Resistance towards the BA
class of HSP90 inhibitors has also been linked to the
multiple drug resistance (MDR) phenotype due to the
up-regulation of the drug efflux pump, p-glycoprotein
(P-gp or MDR1), demonstrating that certain HSP90
inhibitors can be substrates for MDR1, although
mutations are not required (Kim et al., 2015; Zhang
et al., 2005). In addition, resistance towards the qui-
none-containing BAs can be attributed to low levels of
NAD(P)H: quinone oxidoreductase (NQO1), responsi-
ble for metabolizing drugs such as 17-AAG, to their
more potent semiquinone and hydroquinone forms,
leading to increased HSP90 inhibition (George et al.,
2005). Moreover, post-translational modification of
HSP90, such as acetylation, has been shown to be crit-
ical in maintaining normal chaperone function, in par-
ticular client protein and co-chaperone binding
(Kovacs et al., 2005; Scroggins et al., 2007).
In addition to de novo resistance, exposure of cancer
cells to anticancer drugs can result in the acquisition
of chemoresistance. This can occur due to induced
genetic mutations as a result of drug pressure or the
active selection and outgrowth of rare populations of
cancer cells possessing a resistant genotype. Moreover,
epigenetic changes can be a crucial driving force
behind the acquisition of drug resistance. Indeed, stud-
ies of drug-resistant cell lines have shown that multiple
changes in histone acetylation and CpG island methy-
lation are present and can be induced by drug treat-
ment (Baker et al., 2005; Wei et al., 2003). These
changes may not only generate cells that are drug
resistant but may also confer growth and survival
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advantages allowing for a more aggressive tumour
phenotype. As repeated administration of HSP90
inhibitors has been required for treatment efficacy,
exemplified by early-phase trials of 17-AAG and sec-
ond-generation HSP90 inhibitors whereby weekly
administration of drugs is carried out for up to
6 months (Dickson et al., 2013; Heath et al., 2008;
Solit et al., 2008), it is imperative to evaluate whether
chronic HSP90 inhibitor treatment results in acquired
resistance and whether this can be suppressed. Previ-
ously, a lung cancer cell line with acquired resistance
towards GA and 17-AAG has been described with the
induction of heat shock proteins being shown to have
an important role in conferring resistance towards 17-
AAG (McCollum et al., 2008). Low NQO1 levels are
also known to play a significant role in the underlying
mechanism of acquired resistance towards 17-AAG in
glioblastoma and melanoma cell lines (Gaspar et al.,
2009). These studies generated cell resistance by rapid
dose escalation of GA or 17-AAG, and although these
models were highly resistant to other BA HSP90 inhi-
bitors, they did not display any cross-resistance to
other structurally distinct classes of HSP90 inhibitor
compounds (Gaspar et al., 2009; McCollum et al.,
2006, 2008). Therefore, identifying mechanisms of
resistance and defining ways to inhibit this, especially
with respect to next-generation HSP90 inhibitors
that are currently in clinical trials, is of high
importance.
In the current study, we have determined that grad-
ual dose escalation of 17-AAG in cancer cell lines
leads to acquired resistance, not only towards 17-AAG
and other BAs, but most significantly towards the
structurally distinct classes of next-generation HSP90
inhibitors such as AUY922. More significantly, we
determined that an important mechanism of resistance
towards acquired resistance towards a wide spectrum
of HSP90 inhibitors is through altered HDAC expres-
sion and that the use of clinically relevant HDAC inhi-
bitors can reverse resistance towards both BA and
next-generation HSP90 inhibitors. These findings rep-
resent an important step towards identifying other
clinically relevant therapies that can be provided in
conjunction with HSP90 inhibitors to increase their
overall efficacy and utility.
2. Materials and methods
2.1. Cell lines and cell culture
The human cancer cell line MDA-MB-435 was a kind
gift from Janet Price (MD Anderson Cancer Centre,
University of Texas, Houston, TX, USA). The
mammary epithelial origin of the MDA-MB-435 cell
line has been questioned in recent years and was
recently reclassified as being melanocytic in origin
rather than mammary (Rae et al., 2007; Ross et al.,
2000) although it is reported to display strong pheno-
typic characteristics of a breast cancer cell line (Cham-
bers, 2009; Sellappan et al., 2004). Despite this, the
MDA-MB-435 cell line still represents a well-charac-
terized model of an advanced mesenchymal cancer cell
phenotype. The human breast cancer cell line MDA-
MB-231 was obtained from ATCC (Manassas, VA,
USA). Both cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Life Technologies,
Grand Island, NY, USA) containing 10% fetal bovine
serum (FBS; Thermo Fisher Scientific, Rockford, IL,
USA) and antibiotic/antimycotic (Life Technologies).
All assays utilized this medium (DMEM/FBS). The
consistency of cell genotypes and identities were con-
firmed by short tandem repeat (STR) profiling per-
formed at Cell Bank Australia (Westmead, NSW,
Australia). For clarity, the cell lines are referred to as
MDA-435 and MDA-231, respectively, from here on.
2.2. Compounds
17-Allylamino-17-demethoxygeldanamycin was obtained
fromMerck-Calbiochem, Darmstadt, Germany; geldan-
amycin (GA), 17-dimethylaminoethylamino-17-demeth-
oxygeldanamycin (17-DMAG), radicicol, LBH589 and
SNDX275 were obtained from LC Labs (Woburn,
MA, USA). Coumermycin A1, novobiocin and tricho-
statin A (TSA) were obtained from Sigma Aldrich (St.
Louis, MO, USA). NVP-AUY922, CCT018159 and
VER50589 were obtained from Cayman Chemicals
(Ann Arbor, MI, USA). The P-gp inhibitor (verapamil)
and the chemotherapeutic agents paclitaxel, doxoru-
bicin and 5-fluorouracil (5-FU) were obtained from
Merck-Calbiochem.
2.3. Growth inhibition studies
Growth inhibition was determined using the sulforho-
damine B (SRB) assay as described by Skehan et al.
(1990). Briefly, 5 9 103 cells were seeded into 96-well
plates in triplicates, allowed to attach overnight, after
which time drug was added to the wells. After three
days of exposure to the drug, cells were fixed with cold
50% trichloroacetic acid (Sigma Aldrich) for 1 h at
4 °C and stained with 0.4% SRB (Sigma Aldrich) in
1% acetic acid for 10 min at room temperature.
Unbound SRB stain was then rinsed with 1% acetic
acid after which the plates were left to air-dry over-
night. SRB stain was then solubilized in 150 lL of
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Tris/HCl (pH 10.5). Absorbance at 550 nm was mea-
sured using a Multiskan FC Absorbance plate reader
(Thermo Fisher Scientific). The IC50 was calculated
using GraphPad Prism (San Diego, CA, USA) as the
drug concentration that inhibited cell growth by 50%
compared to control cell growth.
2.4. Development of 17-AAG acquired resistant
cell lines
MDA-435 and MDA-231 cells were incubated in T75
flasks at 1 9 IC50 concentrations of 0.05 lM and 1 lM
17-AAG, respectively, as previously determined. Sur-
viving MDA-435 cells were allowed to grow to conflu-
ence after which they were passaged into another flask
and the concentration of 17-AAG was increased grad-
ually from 0.1 to 2 lM over 10 incremental steps with
appropriate passaging until cells maintained stable
growth. Similarly, 17-AAG concentration was
increased gradually in the MDA-231 cells from 1 to
6 lM. Untreated cells and cells treated with vehicle
control were serially passaged along with 17-AAG-
treated cells; no changes in phenotype or sensitivity to
17-AAG were observed in the control and vehicle-trea-
ted cells. After the cells were confirmed to be stably
resistant to 17-AAG by growth inhibition assays, cells
were grown in 17-AAG-free DMEM/FBS. The consis-
tency of cellular genotypes and identities were con-
firmed by short tandem repeat (STR) profiling
performed at Cell Bank Australia (Westmead, NSW,
Australia).
2.5. Western blot analysis
Western blot analysis was performed as described pre-
viously (Price et al., 2005). Briefly, cells were plated in
six-well plates, allowed to adhere overnight and then
treated as described. Cells were rinsed twice with ice-
cold PBS, lysed and lifted from the plate by scraping
in modified RIPA lysis buffer (50 mM Tris/HCl,
150 mM NaCl, 1% NP-40, 0.25% sodium deoxy-
cholate) containing protease and phosphatase inhibi-
tors (Sigma Aldrich). After two-minute sonication
(4 9 30 s pulses) at 4 °C in a sonicating water bath,
the lysate was clarified by centrifugation (14 500 g) for
15 min at 4 °C. Total protein concentration was deter-
mined using bicinchoninic acid assay according to the
manufacturer’s protocol (Thermo Fisher Scientific). To
prepare samples for SDS/PAGE, SDS sample buffer
containing reducing agent (Life Technologies) was
added to the protein samples which were then boiled
for 5 min and centrifuged. Protein samples were then
separated by one-dimensional SDS/PAGE on a 4–12%
gradient acrylamide gel (Life Technologies). The sepa-
rated proteins were then transferred to polyvinylidene
difluoride membranes (Merck-Millipore, Bayswater,
Vic., Australia), blocked with 3% skim milk and
probed with primary antibodies at 4 °C overnight and
then at room temperature with peroxidase-conjugated
secondary antibodies (Thermo Fisher Scientific) for
1 h. Proteins were visualized by an ECL detection sys-
tem according to the manufacturer’s protocol (Thermo
Fisher Scientific). All antibodies were purchased from
commercial sources. Antibodies that detected IGF-1R
(#3027), AKT (#9272), phosphorylated AKT (#4058),
EGFR #2232), PDK (#3062), HDAC1 (#5356),
HDAC3 (#5113), HDAC4 (#7628), HDAC5 (#2082),
HDAC6 (#7558), and acetylated histone H3 (Lys27)
(#4353) were purchased from Cell Signaling Technolo-
gies (Danvers, MA, USA). Antibodies that detected
cyclin B1 (554176), CDK2 (610145) and pan-actin
(612656) were purchased from BD Pharmingen (CA,
USA), and antibodies that detected HSP27 (ADI-SPA-
803) and HSP70 (ADI-SPA-812) were purchased from
Enzo Life Science (San Diego, CA, USA). Anti-mouse
IgG, anti-rabbit IgG and anti-goat IgG HRP-conju-
gated secondary antibodies were obtained from
Thermo Fisher Scientific.
2.6. Immunoprecipitation
Cell lysates were prepared as described previously and
precleared with protein A/Sepharose beads (Merck-
Millipore) for 1 h at 4 °C after which the protein con-
centration was measured as described previously. Pre-
cleared lysate (0.5 mg) was added to 50 lL of
antibody-bead slurry and rotated overnight at 4 °C.
Antibody complexes were washed thrice with lysis buf-
fer and then resuspended in sample buffer. Acetylated
lysine residues of a number of HSP90 isoforms were
determined by SDS/PAGE and western blotting. Anti-
bodies used included HSP90 (ADI-SPA-835), GRP94
(ADI-SPA-850) and TRAP1 (ADI-SPA-971) obtained
from Enzo Life Science, and acetylated lysine (#9441)
was obtained from Cell Signaling Technologies.
2.7. Semiquantitative qPCR and primers
Total RNA was isolated using the Qiagen RNeasy kit
according to the manufacturer’s instructions (Qiagen,
Germantown, MD, USA). One to two micrograms of
total RNA was used to synthesize cDNA using the
superscript VILO cDNA synthesis kit according to the
manufacturer’s instructions (Life Technologies). The
synthesized cDNA underwent PCR amplification using
the Expand High Fidelity PCR System (Roche
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Applied Science, Indianapolis, IN, USA). The primers
used were as follows: NQO1 (FWD): 50-GGGATCC
ACGGGGACATGAATG-30, NQO1 (REV): 50-ATTT
GAATTCGGGCGTCTGCTG-30. Amplifications were
performed with the following profile: 95 °C 3 min;
30 9 (95 °C 30 s, 60 °C 30 s, 72 °C 30 s); 72 °C
7 min; ended at 25 °C. The PCR products were run
on 2% agarose gel.
2.8. Statistical analysis
Data are presented as mean  SD. All assays were
analysed by the unpaired Student’s t-test using Graph-
Pad Prism. Significance is represented as *P < 0.05,
**P < 0.01 and ***P < 0.001.
3. Results
3.1. 17-AAG chronic exposure leads to cancer cell
acquired resistance towards 17-AAG and other
benzoquinone ansamycin HSP90 inhibitors
To investigate whether prolonged treatment with 17-
AAG would lead to an acquired resistance towards
this agent, human cancer cell lines MDA-435 and
MDA-231 were treated with increasing concentrations
of 17-AAG over a period of 20 and 15 weeks, respec-
tively. SRB assays revealed that parental MDA-435
cells were sensitive to 17-AAG with an IC50 of
0.03 lM, while parental MDA-231 cells were relatively
resistant with an IC50 of 0.9 lM, respectively
(Fig. 1A,B; Table 1). Cells that survived prolonged
17-AAG exposure and became stably resistant in vitro
to the highest concentrations of 17-AAG were desig-
nated MDA-435R and MDA-231R, and these cells
had IC50 concentrations of 7.12 and 10.35 lM, respec-
tively (Fig. 1A,B; Table 1). Thus, MDA-435R and
MDA-231R cells displayed high levels of 17-AAG
resistance with resistance indices (RI = IC50 resistant
line/IC50 parental line) of 195 and 7.2, respectively.
These 17-AAG-resistant cells also displayed significant
resistance towards other structurally related HSP90
inhibitors such as other members of the BA family.
For example, towards 17-DMAG, the MDA-435R
and MDA-231R had RIs of 12 and 24, respectively
(Fig. 1C,D; Table 1). Moreover, the resistant cells
showed a low but significant level of resistance
towards GA with RIs of 3.8 and 5.3 for MDA-435R
and MDA-231R, respectively (Fig. 2; Table 1). The
IC50 values for all cell lines to 17-AAG structurally
related drugs are summarized in Table 1. These data
demonstrate that chronic treatment with 17-AAG
leads to not only resistance towards 17-AAG, but
also the development of cross-resistance towards
structurally related BA HSP90 inhibitors in the cancer
cell lines tested.
To identify whether resistance was specific to BA
HSP90 inhibitors and not due to the gain of a mul-
tidrug-resistant phenotype through increased levels and/
or activity of ATP-dependent drug efflux pumps such as
p-glycoprotein 1 (P-gp; MDR1; ABCB1), we deter-
mined IC50 values for chemotherapeutic agents known
to be substrates of efflux pumps. Examination of cis-
platin, paclitaxel, doxorubicin and 5-FU in both the
MDA-435R and MDA-231R demonstrated that there
was no significant alteration in the response of the cells
to these agents with the exception of MDA-231R cells
which were actually increased in their sensitivity
towards doxorubicin (Table 2). Further support for this
was our observation that the use of verapamil, a calcium
channel blocker which inhibits P-gp, failed to alter the
resistance of MDA-435R or MDA-231R cells towards
17-AAG (Fig. 3A,B, respectively). Therefore, taken
together, these results indicated that the resistance was
not mediated via a multidrug efflux pump mechanism.
3.2. Sustained expression of HSP90 client
proteins in MDA-435R and MDA-231R cells with
17AAG treatment
To investigate the molecular impact of acquired resis-
tance towards 17-AAG, we examined steady-state
levels of HSP90 client proteins as well as during 17-
AAG treatment of the parental and resistant cell
lines. Parental MDA-435 and resistant MDA-435R
cells were treated with 17-AAG at 0.1 lM (~ 5 9 IC50
of parental line) and 30 lM (~ 5 9 IC50 of the resis-
tant cell line). Treatment with 0.1 lM of 17-AAG for
24 h resulted in the depletion of the HSP90 client
proteins IGF-1R, Akt, cyclin B1 and PDK in the
parental MDA-435 cells, which was not evident in
the MDA-435R cells (Fig. 4A). Induction of HSP70
and HSP27 was observed in both the parental and
resistant cells; however, notably in the MDA-435R
cells, a lower degree of induction was observed
(Fig. 4A). When treated with 30 lM of 17-AAG
(~ 5 9 IC50 of MDA-435R), depletion of the client
proteins was observed in the MDA-435R (Fig. 4B).
The induction of HSP70 and HSP27 was evident in
both cell lines treated at 30 lM of 17-AAG, although
the induction was lower in MDA-435R when com-
pared to parental cells (Fig. 4B). In a similar manner,
parental MDA-231 and resistant MDA-231R lines
treated with 17-AAG at 5.0 lM (~ 5 9 IC50 of the
parental line) and 50 lM (~ 5 9 IC50 of MDA-231R)
displayed similar results (Fig. 4C,D). Of note, the
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overall level and induction of HSP27 was markedly
lower in the MDA-231R cells as was observed in the
MDA-435R cells. These data demonstrate that
HSP90 client protein levels are more stable in
resistant cells upon 17-AAG treatment as a conse-
quence of acquired resistance. Furthermore, lower
HSP levels, especially that of HSP27, may confer a
survival advantage in the presence of 17-AAG.
Fig. 1. Acquired resistance of MDA-435 and MDA-231 cells towards 17-AAG and 17-DMAG. Dose–response curves and resistance index
(RI = IC50 ratio relative to parental cell line) for MDA-435- and MDA-435R-resistant cells treated for 3 days with 17-AAG (A) and 17-DMAG
(C). MDA-231- and MDA-231R-resistant cells treated for 3 days with 17-AAG (B) and 17-DMAG (D). Growth curves, representative of four
independent experiments; bars, SD. Columns, mean of four independent experiments; bars, SD. *P < 0.05, **P < 0.01, ***P < 0.001 using
Student’s t-test.
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3.3. NQO1 is down-regulated in 17-AAG-resistant
cells
In the light of the significant level of resistance to
BAs, we examined the expression of NQO1 in the
resistant cells as it has been previously shown to be a
major mediator of resistance towards BA HSP90 inhi-
bitors (Gaspar et al., 2009). NQO1 mRNA expression
was significantly decreased in the MDA-435R cells
compared to the parental MDA-435 cells as shown by
semiquantitative RT-PCR (Fig. 5A). However, inter-
estingly, no difference in the mRNA expression levels
of NQO1 was observed between MDA-231 and MDA-
231R cells. These results indicate that decreased
NQO1 expression may be a determinant of acquired
resistance towards 17-AAG and other BAs in the
Table 1. Sensitivity of parental and resistant lines of MDA-435 and MDA-231 cancer cell lines to benzoquinone ansamycins (BAs) and
structurally unrelated HSP90 inhibitors, as determined by IC50 values.
IC50 (lM)
MDA-435 MDA-435R P-value MDA-231 MDA-231R P-value
17-AAG 0.03  0.01 7.12  1.47 0.001*** 0.9  0.27 8.65  1.38 0.009**
17-DMAG 0.054  0.009 0.66  0.31 0.026* 0.07  0.01 1.44  0.42 0.005**
GA 0.032  0.003 0.12  0.02 0.001*** 0.07  0.03 0.37  0.1 0.008**
Radicicol 0.22  0.01 0.8  0.16 0.011* 0.31  0.08 0.83  0.04 0.015*
CCT018159 8.02  2.21 21.08  2.36 0.0003*** 9.08  1.64 31.25  3.25 0.0005***
VER50589 0.1  0.02 0.34  0.05 0.002** 0.15  0.03 0.7  0.21 0.012*
NVP-AUY922 0.013  0.003 0.021  0.003 0.05* 0.028  0.007 0.042  0.003 0.026*
Novobiocin 293.23  44.13 351.53  37.4 0.962 353.73  75.16 316.57  40.75 0.456
Coumermycin A1 14.62  3.04 14.49  3.1 0.156 24.42  9.07 24.5  3.82 0.493
Values are mean  SD of at least three independent experiments. P-values were calculated using standard unpaired Student’s t-test of par-
ental and resistant cell lines. *P-value < 0.05, **P-value < 0.01, ***P-value < 0.001.
Fig. 2. Cross-resistance of MDA-435R and MDA-231R cells towards geldanamycin. Dose–response growth and resistance index of MDA-
435R (A) and MDA-231R (B) treated with geldanamycin determined by SRB assay after 72 h. Curves, representative of three independent
experiments; bars, SD. Columns, mean of at least two independent experiments; bars, SD. *P < 0.05, **P < 0.01 and ***P < 0.001 using
Student’s t-test.
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MDA-435R cells as previously reported in other can-
cer cell lines; however, it does not appear to be a mode
of resistance in the MDA-231R cells, indicating other
mechanisms of resistance exist in these cells.
3.4. Acquired resistance towards 17-AAG alters
HDAC levels and acetylation status of histone H3
and HSP90
During the examination of levels of HSP90 client pro-
teins between the MDA-231 parental and MDA-231R
cells, we identified that there were alterations in the
steady-state levels of HDAC family members. A more
extensive analysis of HDAC expression demonstrated
that HDAC 1 and 6 were expressed at higher levels in
MDA-231R cells, while HDAC 5 was significantly
lower (Fig. 5B). Treatment of parental MDA-231 cells
with 17-AAG decreased HDAC levels; however, as
with other HSP90 client proteins, 17-AAG had less
impact upon HDAC levels in the MDA-231R cells
(Fig. 5B). The expression of HDAC 3 and 4 remained
unchanged at both steady-state levels or after 17-AAG
treatment in MDA-231 and MDA-231R cells
(Fig. 5B). Interestingly, examination of the acetylation
status of HSP90 demonstrated that despite increased
levels of HDAC6 and HDAC1 in the MDA-231R
cells, HSP90 was actually increased in its acetylation
status, while 17-AAG treatment decreased the acetyla-
tion levels of HSP90 in both MDA-231 and MDA-
231R cells (Fig. 5C). In other members of the HSP90
Table 2. Sensitivity of parental and resistant lines of human cancer cells commonly used chemotherapeutic agents.
IC50 (lM)
MDA-435 MDA-435R P-value MDA-231 MDA-231R P-value
Cisplatin 9.23  0.84 12.26  2.6 0.181 12.04  1.94 6.89  1.09 0.083
Paclitaxel 0.0027  0.0006 0.003  0.0006 0.568 0.0095  0.004 0.0045  0.0017 0.145
Doxorubicin 0.15  0.03 0.17  0.06 0.611 0.12  0.02 0.07  0.01 0.014*
5-FU 5.98  0.74 9.39  2.55 0.09 17.59  4.87 26  4.20 0.086
Values are mean  SD of at least three independent experiments. P-values were derived from Student’s t-test of parental and resistant cell
lines.
Fig. 3. Inhibition of P-gp by verapamil does not sensitize resistant cells towards 17-AAG. Dose–response growth and resistance index of
MDA-435R (A) and MDA-231R (B) treated with 17-AAG alone or 17-AAG with 25 mM of verapamil were determined by SRB assay after
three days. Curves, representative of at least two independent experiments; bars, SD. Columns, mean of at least two independent
experiments; bars, SD. *P < 0.05, **P < 0.01 and ***P < 0.001 using Student’s t-test.
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family, only limited levels of acetylation were identified
and no alteration was detected in the endoplasmic
reticulum (ER) (Fig. 5D) and mitochondria isoforms
of HSP90, namely GRP94 (HSPC4) (Fig. 5D) and
TRAP1 (HSPC4) (Fig. 5E), respectively. However,
examination of acetylated histone 3 (Ac-H3) demon-
strated that decreased acetylation was evident in the
MDA-231R cells when compared with the MDA-231
parental cells (Fig. 5F). Treatment of both parental
and resistant cells with 17-AAG increased H3 acetyla-
tion; however, there was a marked differential between
the parental and resistant cell lines (Fig. 5F).
3.5. Inhibition of HDACs in MDA-231R cells
increases sensitivity towards HSP90 inhibitors
In the light of the altered HDAC expression and
acetylation status of the MDA-231R cells, we investi-
gated whether this may be a contributing factor to the
acquired resistant phenotype. To test this, we exam-
ined whether pharmacological inhibition of HDAC
family members would reverse HSP90 inhibitor resis-
tance. We initially utilized the pan-HDAC inhibitor
LBH589 (panobinostat) and demonstrated that treat-
ment of resistant MDA-231 cells with LBH589
(10 nM) in combination with either 17-AAG (Fig. 6A)
or 17-DMAG (Fig. 6B) resulted in a significant rever-
sal of resistance in the MDA-231R cells towards these
BA HSP90 inhibitors as shown by decreased cell sur-
vival and RI (Fig. 6A,B). Interestingly, no significant
change in the de novo resistance of the parental MDA-
231 cells was observed towards either 17-AAG or 17-
DMAG when combined with LBH589.
In addition to using pan-HDAC inhibitors, we also
utilized SNDX-275 (entinostat, formerly MS-275),
which targets class I HDACs, including HDAC1, up-
regulated in the MDA-231R cells (Fig. 5B); however,
it does not inhibit HDAC6 (Wardley et al., 2010;
Younes et al., 2011). Consistent with class I HDAC
activity being involved in acquired HSP90 inhibitor
resistance, SNDX-275 (1 lM) inhibited 17-AAG resis-
tance in the MDA-231R cells (Fig. 6C). Notably, as
with LBH589, the SNDX-275 HDAC inhibitor did
not impact on the sensitivity of parental MDA-231
cells towards 17-AAG (Fig. 6). The alteration in IC50
values of the MDA-231R treated in combination with
Fig. 4. Molecular effects of HSP90 inhibition by 17-AAG on HSP90 client proteins in parental and resistant cell lines. MDA-435 parental and
resistant MDA-435R cells treated with 0.1 lM of 17-AAG (~ 5 9 17-AAG IC50 concentrations of the parental cell line) (A) and with 30 lM of
17-AAG (~ 5 9 17-AAG IC50 concentrations of the resistant cell line) (B). MDA-231 parental and resistant MDA-231R cells treated with
5.0 lM of 17-AAG (~ 5 9 17-AAG IC50 concentrations of the parental cell line) (C) and with 50 lM of 17-AAG (~ 5 9 17-AAG IC50
concentrations of the resistant cell line) (D). Total cell lysates were collected at the indicated time-points and analysed by western blotting.
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HDAC inhibitors is consistent with the up-regulation
and activity of HDACs, including the class I HDACs
such as HDAC 1, contributing to acquired resistance
towards BA HSP90 inhibitors (Table 3).
3.6. 17-AAG-resistant cells are cross-resistant
with next-generation HSP90 inhibitors
structurally unrelated to benzoquinone
ansamycins
As decreased NQO1 expression is limited to conferring
resistance towards BAs, we sought to investigate
whether MDA-435R and MDA-231R displayed cross-
resistance with other HSP90 inhibitors that were struc-
turally unrelated to GA, 17-AAG, and 17-DMAG,
including next-generation HSP90 inhibitors currently
in clinical trial. Interestingly, both MDA-435R and
MDA-231R cells were resistant to the HSP90 inhibitor
radicicol, an antibiotic with a resorcinol scaffold and
structurally unrelated to that of the BAs (Table 1). We
also tested the sensitivity of the resistant cell lines to
the resorcinylic compound, CCT018159, and the
structure-based designed pyrazole resorcinols
VER50589 and AUY922, which have been shown to
be more potent than GA derivatives in inhibiting
HSP90 with their cellular potency being independent
of NQO1 expression (Brough et al., 2007; Eccles et al.,
2008; Sharp et al., 2007). Interestingly, both MDA-
435R and MDA-231R cells showed significant resis-
tance towards CCT018159 and VER50589 and to a
lesser extent AUY922 (Table 1). This is the first report
to demonstrate acquired resistance towards HSP90
inhibitors structurally unrelated to BAs in cancer cells.
Of note, as MDA-435R cells were also significantly
resistant to the resorcinylic compounds, additional
mechanisms of resistance other than reduced NQO1
levels are conferring resistance to non-BA HSP90 inhi-
bitors in the cells.
In contrast to resistance towards the N-terminal
ATPase HSP90 inhibitors, the resistant cell lines had
no alteration in their response to known HSP90 inhibi-
tors that are known to target the C terminus of
HSP90, namely novobiocin and coumermycin A1
(Table 1).
Fig. 5. Altered NQO1 levels, HDAC family member expression and altered acetylation status in 17-AAG-resistant cell lines. Analysis of
parental and resistant cell lines demonstrated altered expression levels of a number of molecules. Semiquantitative PCR demonstrated that
the expression levels of NQO1 in resistant MDA-435 cells were decreased when compared with parental cells, while no alteration was
noted between MDA-231 and MDA-231R cell lines (A). Western blot analysis of parental and resistant MDA-231 total cell lysates examining
levels of HDAC family members in the presence and absence of 17-AAG for a period of 24 h (B). Analysis of acetylated HSP90 by
immunoprecipitation of HSP90 and western blot analysis with antiacetylated lysine antibody of total cell lysates of parental and resistant
MDA-231 cells treated with and without 17-AAG demonstrated increased acetylated HSP90 (C). Analysis of acetylation of Grp94 (D) and
Trap1 (E) by immunoprecipitation and western blot analysis of MDA-231 and MDA-231R total cell lysates demonstrated no alteration in
acetylation status. Acetylated lysine residue was detected by western blotting. Western blot analysis of acetylated histone 3 in parental and
resistant MDA-231 cells treated with and without 17-AAG demonstrated decreased nuclear acetylation (F).
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3.7. Pharmacological Inhibition of HDACs reduces
resistance towards HSP90 inhibitors structurally
unrelated to benzoquinone ansamycins
To determine whether HDAC activity was not only
involved in resistance towards BA HSP90 inhibitors
but also towards the structurally distinct as well as
next-generation HSP90 inhibitors, we assessed whether
resistance towards radicicol and CCT018159 could be
inhibited through the cotreatment of MDA-231R
cells with the HDAC inhibitor LBH589. As with 17-
AAG and 17-DMAG, pharmacological inhibition of
HDAC family members in the MDA-231R cells
resulted in the reversal of resistance towards radicicol
(Fig. 7A; Table 3) and CCT018159 (Fig. 7B; Table 3).
Consistent with previous results, LBH589 did not
Fig. 6. Inhibition of HDACs resensitizes MDA-231R-resistant cells towards 17-AAG and 17-DMAG. Dose response and resistance index (RI)
of MDA-231 and MDA-231R cells treated with the pan-HDAC inhibitor LBH589 (10 nM) in combination with 17-AAG (A) or 17-DMAG (B) for
a period of 72 h. MDA-231 and MDA-231R cells treated with 17-AAG (C) in combination with the more specific HDAC inhibitor SNDX275
(1 lM) that targets class I HDACs. Growth curves, representative of four independent experiments; bars, SD. Columns, mean of four
independent experiments; bars, SD. *P < 0.05, **P < 0.001 using Student’s t-test.
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increase the sensitivity of the MDA-231 parental cells
towards either HSP90 inhibitor (Fig. 7; Table 2).
These results demonstrate for the first time that
HDAC inhibition can reverse acquired resistance not
only towards BA HSP90 inhibitors but also to struc-
turally unrelated and next-generation HSP90 inhibi-
tors, thus indicating a role for HDACs in conferring
acquired resistance towards diverse classes of HSP90
inhibitors.
4. Discussion
Therapeutically targeting HSP90 as an anticancer
strategy has been a highly active area of research in
recent years and has resulted in the generation of a
number of clinically relevant HSP90 inhibitors, many
of which have, or are progressing through clinical tri-
als (Tatokoro et al., 2015; Whitesell et al., 2012).
Despite optimism that HSP90 inhibitors would repre-
sent potent anticancer agents, many HSP90 inhibitor
clinical trials have only shown modest activities or
have failed to meet clinical endpoints (Cercek et al.,
2014; Heath et al., 2008; Johnson et al., 2015; Rama-
lingam et al., 2015; Solit et al., 2008). A common
problem associated with reduced treatment efficacy in
tumours with the majority of anticancer treatments is
the development of drug resistance. To date, few stud-
ies have systematically addressed this problem with
respect to HSP90 inhibitors and none have examined
acquired resistance towards next-generation HSP90
inhibitors. Therefore, the current study aimed to gen-
erate models of acquired resistance towards the HSP90
inhibitor, 17-AAG, identify the extent of cross-
resistance with conventional chemotherapeutics and
next-generation HSP90 inhibitors and seek to identify
potential mechanism of resistance.
Our data demonstrated that chronic treatment of
cancer cell lines with 17-AAG led to acquired resis-
tance towards not only 17-AAG but also to a range of
other structurally related HSP90 inhibitors. A highly
significant finding of the study was that both MDA-
435R and MDA-231R cell lines were also cross-resis-
tant to HSP90 inhibitors structurally unrelated and
chemically distinct to the BAs, including radicicol and
next-generation HSP90 inhibitors CCT018159,
VER50589 and AUY922. To our knowledge, this is
the first report of cancer cells with acquired resistance
that spans different classes of HSP90 inhibitors. How-
ever, it was noted that this cross-resistance did not
include C-terminal HSP90 inhibitors such as novo-
biocin and coumermycin A1 as the resistant cells
retained similar IC50 values towards these compounds.
Although this is the first study to demonstrate resis-
tance to radicicol and next-generation HSP90 inhibi-
tors such as VER50589 and AUY-922, acquired
resistance towards 17-AAG has been previously
reported in lung, glioblastoma and melanoma cell lines
(Gaspar et al., 2009; McCollum et al., 2008). As with
the current study, these cells were found to be cross-
resistant with other members of the BAs, such as 17-
DMAG and GA; however, unlike our results, they
were not identified as cross-resistant to structurally
unrelated HSP90 inhibitors.
Consistent with previous studies that decreased
expression of the quinone-reducing enzyme, NQO1,
which metabolizes HSP90 inhibitors from the BA
family to more potent hydroquinone forms, was a
mode of resistance towards 17-AAG and 17-DMAG
Table 3. Sensitivity of MDA-231 parental and resistant lines towards benzoquinone ansamycins (BAs) and structurally unrelated HSP90
inhibitors and the impact of HDAC nhibtors as determined by IC 50 values.
IC50 (lM)
MDA-231 P-value MDA-231R P-value
17-AAG + Veh. 0.53  0.04 0.8 10.58  0.71 0.01**
17-AAG + LBH589 0.57  0.14 5.64  0.9
17-DMAG + Veh. 0.03  0.004 0.7 0.58  0.06 0.013*
17-DMAG + LBH589 0.02  0.003 0.08  0.003
17-AAG + Veh. 0.55  0.06 0.9 11.64  0.85 0.02*
17-AAG + SNDX275 0.59  0.08 7.62  0.29
Radicicol + Veh. 0.06  0.01 0.4 0.51  0.13 0.047*
Radicicol + LBH589 0.05  0.0007 0.24  0.03
CCT018159 + Veh. 2.75  0.46 0.7 20.92  1 0.008**
CCT018159 + LBH589 2.52  0.36 9.78  0.02
Values are mean  SD of at least three independent experiments. P-values were derived from Student’s t-test of parental and resistant cell
lines.
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(Gaspar et al., 2009), we found NQO1 to be signifi-
cantly reduced in MDA-435R cells. However, NQO1
expression remained unchanged in the MDA-231R
cells, suggesting that there were other mechanisms of
resistance towards BA members in these cells. Previ-
ously identified mechanisms of resistance such as
increased P-gp expression, an increased heat shock
response and up-regulation of HSP27 were not mecha-
nisms by which HSP90 inhibitor resistance was
achieved in the MDA-231 cells (Gaspar et al., 2009;
McCollum et al., 2006, 2008).
Identification of alterations in the levels of HDAC
family members led us to hypothesize that acquired
cell resistance towards different classes of N-terminal
HSP90 inhibitors may be due to altered acetylation
levels of HSP90 itself or the impact of that HDACs
have upon the epigenetic regulation of gene expression.
Previous reports have shown that hyperacetylation of
HSP90 lysine residues can affect co-chaperone associa-
tion, ATP binding and chaperone function, leading to
reduced HSP90 function and increased client protein
degradation (Rao et al., 2008). It has also been shown
that hyperacetylation can result in increased binding of
17-AAG to HSP90 resulting in increased inhibition
and client protein degradation (Rao et al., 2008). The
mainly cytosolic class IIb HDAC family member
HDAC6 has been identified as one of the main
deacetylases of HSP90 (Scroggins et al., 2007). In
addition, class I HDAC family member, HDAC1, also
has the potential to regulate HSP90 acetylation (Zhang
et al., 2013). Broadly, it is thought that acetylation of
HSP90 results in a lost or weakened interaction with
its client proteins, leading to their instability and
degradation (Kramer et al., 2014; Rao et al., 2008).
Consistent with this, studies have shown that inhibi-
tion or knockdown of HDAC6 leads to increased
acetylation of HSP90 and decreased activity (Kramer
et al., 2014; Rao et al., 2008). However, this linear
relationship between HSP90 hyperacetylation and
decreased HSP90 activity and degradation of client
proteins has been questioned, with recent evidence sug-
gesting a more complex relationship between HSP90
hyperacetylation and activity such that in some cell
types, hyperacetylation of HSP90 can lead to increased
Fig. 7. Inhibition of HDACs resensitizes MDA-231R-resistant cells towards structurally unrelated to the BAs and next-generation HSP90
inhibitors. Dose response and resistance index of cells treated with radicicol (A) or with CCT018159 (B) in combination with LBH589 (10 nM)
for a period of 72 h. Growth curves, representative of four independent experiments; bars, SD. Columns, mean of four independent
experiments; bars, SD. *P < 0.05, **P < 0.01 using Student’s t-test.
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client protein levels (Kramer et al., 2014). Our finding
that both HDAC6 and HDAC1 are increased at the
protein level in the MDA-231R cells would suggest
that HSP90 should have lower steady-state acetylation
levels; however, counterintuitively, we found that
HSP90 was more hyperacetylated in the MDA-231R
cells than in the MDA-231 parental cells. Although
the mechanism of this is not known, we speculate that
this may be due to an overall net increase in histone
acetyltransferase (HAT) activity over HDAC activity
with respect to HSP90. Indeed, acetylation homeosta-
sis in cells is a tightly regulated process with HDAC
and HAT levels maintained in a fine balance (Peserico
and Simone, 2011). HATs that target HSP90 remain
largely unknown to date; however, the acetyltrans-
ferase p300 has been shown to be responsible for
acetylating HSP90 at multiple sites (Yang et al., 2008).
The possible role of p300 or other HATs in the regula-
tion of HSP90 acetylation and resistance to HSP90
inhibitors requires further elucidation. No significant
changes in the acetylation status of other HSP90 iso-
forms, namely GRP94 and TRAP1, localized to the
ER and mitochondria, respectively, were evident in
our studies.
Although there has been much emphasis within the
field on the role of HDACs in the direct regulation of
HSP90 activity, HDACs are intimately associated with
transcriptional regulation through their ability to mod-
ify chromatin, alter transcription factor activity and
impact upon transcriptional elongation (Greer et al.,
2015; Wang et al., 2009). HDAC1 localization is pre-
dominantly nuclear and has been implicated in the regu-
lation of gene expression (Zupkovitz et al., 2006), and
while HDAC6 is known to be largely cytoplasmic,
recent evidence indicates that it shuttles between the
cytoplasm and nucleus and also plays a critical role in
the regulation of gene expression (Greer et al., 2015;
Liu et al., 2012; Wang et al., 2009). Consistent with
increased HDAC activity at the nuclear level, acetyla-
tion of histone 3 in the resistant cells was decreased,
while 17-AAG treatment of both parental and resistant
cells resulted in decreased HDAC expression and
increased histone acetylation, although notably less in
the resistant cells. Therefore, although previous studies
showed that HDAC inhibition can sensitize leukaemia
cells towards 17-AAG through HSP90 hyperacetylation
resulting in increased 17-AAG binding and increased
client protein degradation (Rao et al., 2008; Scroggins
et al., 2007), we postulate that acquired HSP90 inhibi-
tor resistance is mediated by an epigenetic mechanism.
That is, through altered HDAC activity and the subse-
quent influence on the expression of a wide number of
genes, HDACs are able to mediate a HSP90 inhibitor
cell resistance phenotype. To investigate this further, we
are currently examining gene expression profiles of resis-
tant cells associated with resistance, which can be
reversed with HDAC inhibition.
In summary, our results demonstrate for the first
time that HDACs are involved in the underlying
mechanism of acquired resistance towards multiple
classes of HSP90 inhibitors, potentially through an
epigenetic mechanism rather than through a direct
impact upon HSP90 acetylation status; however, the
latter cannot be fully discounted. These findings do,
however, provide further support towards examining
the use of HDAC inhibitors in combination with
HSP90 inhibitors to overcome potential acquired resis-
tance that may occur, thus increasing the therapeutic
efficacy of current clinically relevant HSP90 inhibitors.
Acknowledgements
This work was supported by an Australian National
Health and Medical Research Council Project Grant
(606549), Cancer Council Victoria Grant-in-Aid
(545969), RD Wright Fellowship No. 395525 (to JTP),
an Australian Post-Graduate Award (to RCC) and an
NBCF Early Career Fellowship (to KLB).
Author contributions
RCC and JTP conceived and designed the study.
RCC, JLV, BJL and CHN performed the experiments.
RCC, MMK and KB analysed and interpreted the
data. RCC and JTP wrote the manuscript.
References
Baker EK, Johnstone RW, Zalcberg JR and El-Osta A
(2005) Epigenetic changes to the MDR1 locus in
response to chemotherapeutic drugs. Oncogene 24,
8061–8075.
Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K,
Cansfield JE, Cheung K-MJ, Collins I, Davies NG and
Drysdale MJ (2007) 4, 5-diarylisoxazole Hsp90
chaperone inhibitors: potential therapeutic agents for
the treatment of cancer. J Med Chem 51, 196–218.
Butler LM, Ferraldeschi R, Armstrong HK, Centenera
MM and Workman P (2015) Maximizing the
therapeutic potential of HSP90 inhibitors. Mol Cancer
Res 13, 1445–1451.
Cercek A, Shia J, Gollub M, Chou JF, Capanu M, Raasch
P, Reidy-Lagunes D, Proia DA, Vakiani E, Solit DB
et al. (2014) Ganetespib, a novel Hsp90 inhibitor in
patients with KRAS mutated and wild type, refractory
metastatic colorectal cancer. Clin Colorectal Cancer 13,
207–212.
580 Molecular Oncology 11 (2017) 567–583 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
HDAC activity and HSP90 inhibitor resistance R. C. Chai et al.
Chambers AF (2009) MDA-MB-435 and M14 cell lines:
identical but not M14 melanoma? Cancer Res 69,
5292–5293.
Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J,
Chung F, Korn J, Ruddy D and Guo R (2013)
Targeting HSF1 sensitizes cancer cells to HSP90
inhibition. Oncotarget 4, 816–829.
Dickson M, Okuno S, Keohan M, Maki R, D’Adamo D,
Akhurst T, Antonescu C and Schwartz G (2013) Phase
II study of the HSP90-inhibitor BIIB021 in
gastrointestinal stromal tumors. Ann Oncol 24, 252–
257.
Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G,
Valenti M, Patterson L, de Haven Brandon A, Gowan
S and Boxall F (2008) NVP-AUY922: a novel heat
shock protein 90 inhibitor active against xenograft
tumor growth, angiogenesis, and metastasis. Cancer
Res 68, 2850–2860.
Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal
G, Eccles S, Pearson A and Workman P (2009)
Acquired resistance to 17-allylamino-17-
demethoxygeldanamycin (17-AAG, tanespimycin) in
glioblastoma cells. Cancer Res 69, 1966–1975.
George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo
F, Sigua C, Sondarva G, Moscinski L and Atadja P
(2005) Combination of the histone deacetylase inhibitor
LBH589 and the hsp90 inhibitor 17-AAG is highly
active against human CML-BC cells and AML cells
with activating mutation of FLT-3. Blood 105, 1768–
1776.
Greer CB, Tanaka Y, Kim YJ, Xie P, Zhang MQ, Park IH
and Kim TH (2015) Histone deacetylases positively
regulate transcription through the elongation
machinery. Cell Rep 13, 1444–1455.
Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle
S, Kumaraswamy S, Balasis M, Greedy B, Armitage
ES et al. (2005) Abrogation of heat shock protein 70
induction as a strategy to increase antileukemia activity
of heat shock protein 90 inhibitor 17-allylamino-
demethoxy geldanamycin. Cancer Res 65, 10536–10544.
Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar
F, Harper F, Gaskins M, Pitot HC, Tan W and Ivy SP
(2008) A phase II trial of 17-allylamino-17-
demethoxygeldanamycin in patients with hormone-
refractory metastatic prostate cancer. Clin Cancer Res
14, 7940–7946.
Holmes JL, Sharp SY, Hobbs S and Workman P (2008)
Silencing of HSP90 cochaperone AHA1 expression
decreases client protein activation and increases cellular
sensitivity to the HSP90 inhibitor 17-allylamino-17-
demethoxygeldanamycin. Cancer Res 68, 1188–1197.
Jhaveri K, Taldone T, Modi S and Chiosis G (2012)
Advances in the clinical development of heat shock
protein 90 (Hsp90) inhibitors in cancers. Biochem
Biophys Acta 1823, 742–755.
Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker
AW, Patel JD, Kris MG and Riely GJ (2015) Phase I/
II study of HSP90 inhibitor AUY922 and erlotinib for
EGFR-mutant lung cancer with acquired resistance to
epidermal growth factor receptor tyrosine kinase
inhibitors. J Clin Oncol 33, 1666–1673.
Kim HJ, Lee KY, Kim YW, Choi YJ, Lee JE, Choi CM,
Baek IJ, Rho JK and Lee JC (2015) P-glycoprotein
confers acquired resistance to 17-DMAG in lung
cancers with an ALK rearrangement. BMC Cancer 15,
553.
Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT,
Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao
TP (2005) HDAC6 regulates Hsp90 acetylation and
chaperone-dependent activation of glucocorticoid
receptor. Mol Cell 18, 601–607.
Kramer OH, Mahboobi S and Sellmer A (2014) Drugging
the HDAC6-HSP90 interplay in malignant cells. Trends
Pharmacol Sci 35, 501–509.
Liu Y, Peng L, Seto E, Huang S and Qiu Y (2012)
Modulation of histone deacetylase 6 (HDAC6) nuclear
import and tubulin deacetylase activity through
acetylation. J Biol Chem 287, 29168–29174.
Maloney A, Clarke PA and Workman P (2003) Genes and
proteins governing the cellular sensitivity to HSP90
inhibitors: a mechanistic perspective. Curr Cancer Drug
Targets 3, 331–341.
McCollum AK, Teneyck CJ, Sauer BM, Toft DO and
Erlichman C (2006) Up-regulation of heat shock
protein 27 induces resistance to 17-allylamino-
demethoxygeldanamycin through a glutathione-
mediated mechanism. Cancer Res 66, 10967–10975.
McCollum AK, TenEyck CJ, Stensgard B, Morlan BW,
Ballman KV, Jenkins RB, Toft DO and Erlichman C
(2008) P-Glycoprotein-mediated resistance to Hsp90-
directed therapy is eclipsed by the heat shock response.
Cancer Res 68, 7419–7427.
Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E,
Tomaszewski J, Smith A, Rodman L (1997)
Comparison of geldanamycin (NSC-122750) and 17-
allylaminogeldanamycin (NSC-330507D) toxicity in
rats. Proc Am Assoc Cancer Res 38, 308.
Peserico A and Simone C (2011) Physical and functional
HAT/HDAC interplay regulates protein acetylation
balance. J Biomed Biotechnol 2011, 371832.
Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K,
Docherty SE, Myers D, Nakamura A, Waltham MC
and Gillespie MT (2005) The heat shock protein 90
inhibitor, 17-allylamino-17-demethoxygeldanamycin,
enhances osteoclast formation and potentiates bone
metastasis of a human breast cancer cell line. Cancer
Res 65, 4929–4938.
Rae JM, Creighton CJ, Meck JM, Haddad BR and
Johnson MD (2007) MDA-MB-435 cells are derived
from M14 melanoma cells–a loss for breast cancer, but
581Molecular Oncology 11 (2017) 567–583 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
R. C. Chai et al. HDAC activity and HSP90 inhibitor resistance
a boon for melanoma research. Breast Cancer Res
Treat 104, 13–19.
Ramalingam S, Goss G, Rosell R, Schmid-Bindert G,
Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T,
Khuri F et al. (2015) A randomized phase II study of
ganetespib, a heat shock protein 90 inhibitor, in
combination with docetaxel in second-line therapy of
advanced non-small cell lung cancer (GALAXY-1).
Ann Oncol 26, 1741–1748.
Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P,
Mandawat A, Atadja P, Bradner JE and Bhalla K
(2008) HDAC6 inhibition enhances 17-AAG–mediated
abrogation of hsp90 chaperone function in human
leukemia cells. Blood 112, 1886–1893.
da Rocha Dias S, Friedlos F, Light Y, Springer C,
Workman P and Marais R (2005) Activated B-RAF is
an Hsp90 client protein that is targeted by the
anticancer drug 17-allylamino-17-
demethoxygeldanamycin. Cancer Res 65, 10686–10691.
Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM,
DeLuca JK, Schwartz L, Bacik J and Motzer RJ
(2006) A phase II trial of 17-(Allylamino)-17-
demethoxygeldanamycin in patients with papillary and
clear cell renal cell carcinoma. Invest New Drugs 24,
543–546.
Ross DT, Scherf U, Eisen MB, Perou CM, Rees C,
Spellman P, Iyer V, Jeffrey SS, Van de Rijn M,
Waltham M et al. (2000) Systematic variation in gene
expression patterns in human cancer cell lines. Nat
Genet 24, 227–235.
Sato S, Fujita N and Tsuruo T (2000) Modulation of Akt
kinase activity by binding to Hsp90. Proc Natl Acad
Sci U S A 97, 10832–10837.
Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi
S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L
et al. (2007) An acetylation site in the middle domain
of Hsp90 regulates chaperone function. Mol Cell 25,
151–159.
Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills
GB and Yu D (2004) Lineage infidelity of MDA-MB-
435 cells: expression of melanocyte proteins in a breast
cancer cell line. Cancer Res 64, 3479–3485.
Sharp SY, Prodromou C, Boxall K, Powers MV, Holmes
JL, Box G, Matthews TP, Cheung K-MJ, Kalusa A
and James K (2007) Inhibition of the heat shock
protein 90 molecular chaperone in vitro and in vivo by
novel, synthetic, potent resorcinylic pyrazole/isoxazole
amide analogues. Mol Cancer Ther 6, 1198–1211.
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J,
Vistica D, Warren JT, Bokesch H, Kenney S, Boyd
MR (1990) New colorimetric cytotoxicity assay for
anticancer-drug screening. J Natl Cancer Inst 82, 1107–
1112.
Smith V, Hobbs S, Court W, Eccles S, Workman P,
Kelland LR (2001) ErbB2 overexpression in an ovarian
cancer cell line confers sensitivity to the HSP90
inhibitor geldanamycin. Anticancer Res 22, 1993–1999.
Solit DB, Osman I, Polsky D, Panageas KS, Daud A,
Goydos JS, Teitcher J, Wolchok JD, Germino FJ and
Krown SE (2008) Phase II trial of 17-allylamino-17-
demethoxygeldanamycin in patients with metastatic
melanoma. Clin Cancer Res 14, 8302–8307.
Tatokoro M, Koga F, Yoshida S and Kihara K (2015)
Heat shock protein 90 targeting therapy: state of the
art and future perspective. EXCLI J 14, 48–58.
Trepel J, Mollapour M, Giaccone G and Neckers L (2010)
Targeting the dynamic HSP90 complex in cancer. Nat
Rev Cancer 10, 537–549.
Wang M, Shen A, Zhang C, Song Z, Ai J, Liu H, Sun L,
Ding J, Geng M and Zhang A (2016) Development of
heat shock protein (Hsp90) inhibitors to combat
resistance to tyrosine kinase inhibitors through Hsp90-
kinase interactions. J Med Chem 59, 5563–5586.
Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y,
Chiu J, Guo H, Satagopan J, Wilton A et al. (2009)
Increased expression of histone deacetylaces (HDACs)
and inhibition of prostate cancer growth and invasion
by HDAC inhibitor SAHA. Am J Transl Res 1, 62–
71.
Wardley A, Stein R, McCaffrey J, Crown J, Malik Z, Rea
D, Barrett-Lee P and Lee G (2010) Phase II data for
entinostat, a class 1 selective histone deacetylase
inhibitor, in patients whose breast cancer is progressing
on aromatase inhibitor therapy. J Clin Oncol 28,
a1052.
Wei SH, Brown R and Huang TH (2003) Aberrant DNA
methylation in ovarian cancer: is there an epigenetic
predisposition to drug response? Ann N Y Acad Sci
983, 243–250.
Whitesell L and Lindquist SL (2005) HSP90 and the
chaperoning of cancer. Nat Rev Cancer 5, 761–772.
Whitesell L, Santagata S and Lin NU (2012) Inhibiting
HSP90 to treat cancer: a strategy in evolution. Curr
Mol Med 12, 1108–1124.
Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M,
Yarden Y and Neckers L (2001) Sensitivity of mature
Erbb2 to geldanamycin is conferred by its kinase
domain and is mediated by the chaperone protein
Hsp90. J Biol Chem 276, 3702–3708.
Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J,
Atadja P and Bhalla K (2008) Role of acetylation and
extracellular location of heat shock protein 90a in
tumor cell invasion. Cancer Res 68, 4833–4842.
Yong K, Cavet J, Johnson P, Morgan G, Williams C,
Nakashima D, Akinaga S, Oakervee H and Cavenagh
J (2016) Phase I study of KW-2478, a novel Hsp90
inhibitor, in patients with B-cell malignancies. Br J
Cancer 114, 7–13.
Younes A, Kasamon Y, Bociek RG, Lee P, Gore L,
Copeland A, Hernandez-Ilizaliturri F (2011) The
582 Molecular Oncology 11 (2017) 567–583 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
HDAC activity and HSP90 inhibitor resistance R. C. Chai et al.
HDAC inhibitor entinostat (SNDX-275) induces
clinical responses in patients with relapsed or
refractory Hodgkin’s lymphoma: results of ENGAGE
501 Multicenter Phase 2 Study. Blood 118,
2715.
Zhang H, Neely N, Yang Y and Burrows F (2005)
Influence of multidrug resistance proteins on the
antitumor activity of natural and synthetic Hsp90
inhibitors. Clin Cancer Res 11, 9108–9109s.
Zhang J, Xu E and Chen X (2013) TAp73 protein stability
is controlled by histone deacetylase 1 via regulation of
Hsp90 chaperone function. J Biol Chem 288, 7727–
7737.
Zupkovitz G, Tischler J, Posch M, Sadzak I, Ramsauer K,
Egger G, Grausenburger R, Schweifer N, Chiocca S,
Decker T et al. (2006) Negative and positive regulation
of gene expression by mouse histone deacetylase 1. Mol
Cell Biol 26, 7913–7928.
583Molecular Oncology 11 (2017) 567–583 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
R. C. Chai et al. HDAC activity and HSP90 inhibitor resistance
